UFC newcomer Amanda Ribas will be sitting on the sidelines until 2019

Amanda Ribas didn’t even get the chance to make her UFC debut last year before she pulled from “The Ultimate Fighter” finale due to a doping violation from USADA.

Now the 6-1 strawweight will be out until June 2019 after being handed a two year suspension from USADA (United States Anti-Doping Agency) as a result of her positive drug test for Ostarine.

“Ribas, 24, tested positive for ostarine following an out-of-competition urine test conducted on June 7, 2017. Ostarine is a non-Specified Substance in the class of Anabolic Agents and prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency Prohibited List,” USADA officials said in a statement. “Ostarine also known as MK-2866 and Enobosarm, is a non-FDA approved selective androgen receptor modulator (SARM) that is illegally sold in the United States and worldwide as a performance-enhancing substance. Ostarine is not currently available as a prescription medication in any country, and its unauthorized use may carry serious side effects.”

The test Ribas submitted was conducted on June 7, 2017, which resulted in her removal from “The Ultimate Fighter” finale card a month later in Las Vegas. Ribas’ two year suspension is retroactive to the date of her test on June 7, 2017, which means she’ll be eligible to return to action on June 7, 2019.

Ribas’ drug test also falls under the jurisdiction of the Nevada State Athletic Commission, who could impose separate sanctions or fines for the failed drug test.

While Ribas never made her UFC debut, she’s still currently listed on the active fighter roster, which means she’s still subject to year round testing from USADA even under suspension.